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ABSTRACT 
Brain tumors have the highest percentage of thrombosis compared to other types of malignancies. 
Hypercoagulation is a risk for thromboembolic events in patients with malignancy. Hypercoagulation 
conditions are frequently found in patients with malignancy arising from the aptitude of tumor cells to 
activate the coagulation system. This condition can be detected through coagulation markers in the blood. 
This marker is PT, APTT, INR, Fibrinogen and D-Dimer. This research is a descriptive analytic study using 
secondary data from medical records of patients with central nervous system (CNS) tumors. The inclusion 
criteria were CNS tumor patients > 18 years old and had been diagnosed with CNS tumor. Coagulation 
markers are recorded based on the results of the initial laboratory examination upon entering the hospital, 
consisting of D-Dimer, PT, APTT, Fibrinogen, INR. There were 124 research subjects, consisting of 60 
men and 64 women. Most research subjects are in the age range of 40-49 years (54.8%). Hypercoagulation 
conditions were found in 92.74% of study subjects. The most common accompanying condition was 
hypertension (22.6%). There were no significant differences in the hypercoagulable conditions in groups 
with and without accompanying conditions. Hypercoagulation was found in most research subjects. There 
are no factors that influence the hypercoagulation condition in this study. 
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ABSTRAK 
Tumor  otak memiliki presentase kejadian trombosis paling tinggi dibandingkan dengan tipe keganasan 
yang lain. Hiperkoagulasi merupakan suatu resiko untuk kejadian tromboemboli pada penderita dengan 
keganasan. Kondisi Hiperkoagulasi sering ditemukan pada penderita keganasan timbul karena adanya 
kemampuan sel-sel tumor untuk mengaktivasi sistem koagulasi. Kondisi hiperkoagulasi ini dapat dideteksi 
melalui petanda koagulasi pada darah. Petanda koagulasi ini dapat berupa PT, APTT, INR, Fibrinogen dan 
D-Dimer. Penelitian ini merupakan penelitian deskriptif analitik dengan menggunakan data sekunder rekam 
medis penderita tumor susunan saraf pusat (SSP). Kriteria inklusi adalah penderita tumor SSP usia > 18 
tahun dan telah ditegakkan diagnosa tumor SSP. Penanda koagulasi dicatat berdasarkan hasil pemeriksaan 
laboratorium awal saat masuk RS, terdiri dari D-Dimer, PT, APTT, Fibrinogen, INR. Didapatkan 124 
subjek penelitian, yang terdiri dari 60 laki-laki dan 64 perempuan. Sebagian besar subjek penelitian berada 
pada rentang usia 40-49 tahun (54,8%). Kondisi hiperkoagulasi didapatkan pada 92,74% subjek penelitian. 
Kondisi penyerta yang paling sering dijumpai adalah hipertensi (22,6%).  Tidak didapatkan perbedaan 
bermakna terhadap kondisi hiperkoagulasi pada kelompok dengan dan tanpa kondisi penyerta. 
Hiperkoagulasi dijumpai pada sebagian besar subjek penelitian. Tidak didapatkan faktor yang 
mempengaruhi kondisi hiperkoagulasi pada penelitian ini. 
 
Kata kunci:  hiperkoagulasi, kondisi penyerta, petanda koagulasi, tumor SSP 
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1. Introduction 
 
The World Health Organization 
(WHO) establishes cancer as a global health 
problem. Data from the National Cancer 
Institute in 2010-2014 shows that new cases 
of CNS cancer reach 6.4 / 100,000 men and 
women per year.1 In Indonesia the incidence 
of central nervous system tumors is 
increasing each day. With an increase in the 
incidence of these tumors there is also an 
increase in the complications they cause. 
It is well known that tumors are 
associated with thrombosis risk. Brain tumors 
have the highest percentage of thrombosis 
events compared to other types of 
malignancies, which is 26%. 2 
Hypercoagulation is one of the risk factor for 
thromboembolic events in patients with 
malignancy. Hypercoagulation in 
malignancy was first reported in 1865 by 
Armand Trousseau, who first described the 
clinical link between thromboembolic 
disease and malignancy.3 
Hypercoagulation conditions are often 
found in patients with malignancy arising 
from the aptitude of tumor cells to activate 
the coagulation system. The state of 
hypercoagulation reflects the interaction of 
different mechanisms involving the 
activation of various hemostatic physiology 
components. Tumor cells interact with all 
parts of the hemostatic physiology system. 
Tumor cells can directly activate the 
coagulation cascade by producing their own 
procoagulant factors or stimulating the 
prothrombotic nature of other blood cell 
components.4 This hypercoagulable 
condition can be detected through 
coagulation markers in the blood. This 
coagulation marker can be PT, APTT, INR, 
Fibrinogen and D-Dimer.5 This study aims to 
determine the profile of coagulation markers 
and the factors that influence it in patients 
with central nervous system tumors. 
 
2. Methods 
 
 This research is an analytical 
descriptive study using secondary data from 
medical records of patients with central 
nervous system tumors from January 2017 to 
December 2018 at RSUP Mohammad Hoesin 
Palembang. The inclusion criteria were CNS 
tumor patients > 18 years old and diagnosis 
was made based on histopathological 
features. In the case of metastatic tumors, the 
diagnosis is based on imaging in the form of 
a CT scan or MRI. Subjects with a history of 
or currently taking antiplatelet or 
anticoagulant were excluded in this study. 
Coagulation markers are recorded based on 
the results of the initial laboratory 
examination upon entering the hospital, 
consisting of D-Dimer, PT, APTT, 
Fibrinogen, INR. Hypercoagulation is 
defined if there is an increase above the 
normal value of one or more of the 
coagulation markers. Diseases associated 
with hypercoagulation were also noted. Data 
analysis using SPSS 24 for Windows. 
 
3. Results 
 
In this study there were 124 research 
subjects. The mean age of patients with CNS 
tumors was 47.97 ± 12.63 years old. Based on 
age category, most patients were aged 40-59 
years old (54.8%), with the proportion not 
much different between women (51.6%) and 
men (48.4%). As many as 59.7% of study 
subjects had accompanying conditions, with 
the most common accompanying condition 
being hypertension (22.6%). Neurological 
deficits were found in almost all study 
subjects (99.2%). Based on tumor 
characteristics, the proportion of metastatic 
tumors was higher than primary tumors 
(63.7% and 36.3%) with a higher number of 
multiple tumor lesions (59.7%).  
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By location, brain tumors are more 
common than spinal cord tumors (89.5% and 
10.5%). Hypercoagulation conditions were 
found in 92.74% of research subjects. There 
was no significant difference in the 
occurrence of hypercoagulation in groups 
with accompanying conditions and without 
accompanying conditions (p = 0.483). The 
analysis can be seen in table 1. 
 
Table 1. Clinical characteristics of study subjects (n = 124) 
Characteristics Total Frequency  
n (%) 
Hypercoagulation 
n (%) 
No 
Hypercoagulation 
n (%) 
 p value 
Age (Mean±SD) 47,97±12,63 48,58±12,38 40,22±13,98 0,056a 
Age Category     
<40 years old 32(25,8) 27(84,4) 5(15,6) 0,072b 
40-59 years old 68(54,8) 65(95,6) 3(4,4)  
≥60 years old 24(19,4) 23(95,8) 1(4,2)  
Gender     
Male 60(48,4) 56(93,3) 4(6,7) 1,000c 
Female 64(51,6) 59(92,2) 5(7,8)  
With Accompanying 
Conditions 
    
Yes 74(59,7) 70(94,6) 4(5,4) 0,483c 
No 50(40,3) 45(90,0) 5(10,0)  
- Hypertension     
Yes 28(22,6) 27(96,4) 1(3,6) 0,682c 
No 96(77,4) 88(91,7) 8(8,3)  
- Diabetes Melitus     
Yes 5(4,0) 4(80,0) 1(20,0) 0,318c 
Not 119(96,0) 111(93,3) 8(6,7)  
- History of 
TIA/Stroke 
    
Ya 8(6,5) 8(100,0) 0(0,0) 1,000c 
Tidak 116(93,5) 107(92,2) 9(7,8)  
- Atrial Fibrillation     
Yes 3(2,4) 3(100,0) 0(0,0) 1,000c 
No 121(97,6) 112(92,6) 9(7,4)  
- Smoking     
Yes 6(4,8) 6(100,0) 0(0,0) 1,000c 
No 118(95,2) 109(92,4) 9(7,6)  
- Dyslipidemia     
Yes 1(0,8) 0(0,0) 1(100,0) 0,073c 
No 123(99,2) 115(93,5) 8(6,5)  
- Infection     
Yes 24(19,4) 24(100,0) 0(0,0) 0,204c 
No 100(80,6) 91(91,0) 9(9,0)  
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Neurological deficit 
Yes 123(99,2) 115(93,5) 8(6,5) 0,073c 
No 1(0,8) 0(0,0) 1(100,0)  
Tumor Type     
Primary 45(36,3) 42(93,3) 3(6,7) 1,000c 
Metastasis 79(63,7) 73(92,4) 6(7,6)  
Amount of Tumors     
Single 50(40,3) 47(94,0) 3(6,0) 0,739c 
Multiple 74(59,7) 68(91,9) 6(8,1)  
Tumor Location     
Brain 111(89,5) 104(93,7) 7(6,3) 0,239c 
Spinal Medulla 13(10,5) 11(84,6) 2(15,4)  
aIndependent T Test, bMann Whitney, cFischer Exact Test 
 
 
In the group of subjects with hypercoagulation, it was found that most of the subjects (60.87%) 
had aaccompanying conditions, with the most age group being 40-59 years old. There was a 
significant difference in the incidence of hypercoagulation in groups with and without 
accompanying conditions (p = 0.029). The analysis can be seen in table 2.  
 
Table 2. Distribution of Proportions of Hypercoagulation Patients Based on Accompanying 
Conditions (n = 115) 
Characteristics With 
Accompanying 
Conditions 
n (%) 
Without Accompanying 
Conditions 
n (%) 
P 
Value 
Age (Mean±SD) 49,48±13,42 47,17±10,57 0,307a 
Age Category    
<40 years old 17(63,0) 10(37,0) 0,213b 
40-59 years old 34(52,3) 31(47,7)  
≥60 years old 19(82,6) 4(17,4)  
Gender    
Male 37(66,1) 19(33,9) 0,265c 
Female 33(55,9) 26(44,1)  
Tumor Type    
Primary 23(54,8) 19(45,2) 0,309c 
Metastasis 47(64,4) 26(35,6)  
Amount of Tumor    
Single 23(48,9) 24(51,1) 0,029c 
Multiple 47(69,1) 21(30,9)  
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Tumor Location 
Brain 63(60,6) 41(39,4) 1,000d 
Spinal Medulla 7(63,6) 4(36,4)  
Total Neurological Deficits    
1 deficit 14(46,7) 16(53,3) 0,064c 
2 deficits 27(57,4) 20(42,6) 0,532c 
3 deficits 24(72,7) 9(27,3) 0,098c 
4 deficits 5(100,0) 0(0,0) 0,155d 
aIndependent T Test, bMann Whitney, cPearson Chi Square, dFischer Exact Test 
 
In the group of subjects who did not have concomitant conditions, statistical analysis showed a 
significant difference in the age ratio between patients with hypercoagulation (46.03 ± 10.21) and 
without hypercoagulation (35.60 ± 10.14) (p <0.05). While in the other categories include gender, 
type of tumor, amount of tumor and tumor location, there were no significant differences in 
hypercoagulable conditions (p> 0.05). The analysis is shown in table 3. 
 
Table 3. Distribution of Proportion of Patients without Accompanying Conditions with 
Hypercoagulation (n = 50) 
Characteristics without 
Accompanying Conditions 
(n = 50) 
Hypercoagulation 
n (%) 
Without 
Hypercoagulation 
n (%) 
P 
Value 
Age (Mean±SD) 47,17±10,57 35,40±9,99 0,022a 
Age Category    
<40 years old 10(76,9) 3(23,1) 0,140b 
40-59 years old 31(93,9) 2(6,1)  
≥60 years old 4(100,0) 0(0,0)  
Gender    
Male 19(90,5) 2(9,5) 1,000c 
Female 26(89,7) 3(10,3)  
Tumor Type    
Primary 19(86,4) 3(13,6) 0,643c 
Metastasis 26(92,9) 2(7,1)  
Amount of Tumor    
Single  24(88,9) 3(11,1) 1,000c 
Multiple 21(91,3) 2(8,7)  
Tumor Location    
Brain 41(91,1) 4(8,9) 0,423c 
Spinal Medulla 4(80,0) 1(20,0)  
Total Neurological Deficits    
1 deficit 16(88,9) 2(11,1) 1,000c 
2 deficits 20(87,0) 3(13,0) 0,651c 
3 deficits 9(100,0) 0(0,0) 0,570c 
aIndependent T Test, bMann Whitney, cFischer Exact Test 
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4. Discussion 
 
An increased risk of thrombosis is 
associated with changes in blood flow, injury 
to the vascular endothelium and changes in 
blood constitution known as virchow’s triad. 
It is well known that thrombosis and 
malignancy are related by several complex 
pathophysiological mechanisms.5,6,7,8, 
Tumor cells can activate the blood 
coagulation system through several 
mechanisms such as the production of 
procoagulant factors, fibrinolytic activity, 
proagregation, release of proinflammatory 
and proangiogenic cytokines and direct 
interaction with vascular vessels and blood 
cells through adhesion molecules. 
Procoagulant factors produced by tumor cells 
are Tissue Factor (TF) and Cancer 
Procoagulant (CP). In addition, tumor cells 
also produce and secrete a number of normal 
proinflammatory cytokines in vascular 
endothelium, for example TNF-a and IL-1b. 
9,10,11,12 
It is known that malignancy itself is one 
of the conditions underlying 
hypercoagulation. Age and sex are known to 
affect hypercoagulable conditions. Old age 
cause an increased risk of hypercoagulation. 
In America the incidence of 
hypercoagulation that causes symptomatic 
thromboembolism is generally passed down 
higher in men than in women.4.13 In addition, 
several accompanying conditions that affect 
hypercoagulation can sometimes be found 
together in malignant sufferers. These 
accompanying conditions include smoking, 
immobilization, thrombocytosis, pregnancy, 
metabolic diseases such as hypertension, 
DM, atrial fibrillation and infection. With this 
accompanying condition, it certainly 
increases the risk of hypercoagulation in 
patients with CNS tumors. 
The incidence of hypercoagulation in 
malignancies varies depending on the type 
of malignancy itself. Brain tumor is one 
type of malignancy that has a high 
incidence of hypercoagulation. In this 
study hypercoagulation was found in 
92.74% of subjects, where metastatic 
tumors had higher rates than primary 
tumors. This is related to the rate of 
metastasis at this time is much higher 
compared to primary CNS tumors. Old age 
group is the largest proportion of CNS 
tumor events. These results are consistent 
with previous studies by Eppy et al, who 
found the age group of 40-59 years.14 
Research by Goldschmidt et al, also 
showed that the age of most brain tumor 
sufferers was > 50 years (71.4%) .15 
Increased incidence of brain tumors in old 
age related to the length of exposure 
needed by a cell to become malignant or 
decrease the body's defense system 
resulting in a decrease in the immune 
system in protection against disease. Old 
age is associated with hypercoagulation 
which causes venous thromboembolism 
(VTE). Old age is associated with 
increased plasma levels of many blood 
coagulation proteins and disruption of the 
fibrinolysis process.16 
In this study, there was no significant 
difference in the presence or absence of 
accompanying conditions with 
hypercoagulation while not 
hypercoagulation. This is related to the high 
incidence of hypercoagulation in this study 
(92.74%). This result is different from 
previous studies by Eppy et al., which 
showed a large percentage of accompanying 
conditions in patients with hypercoagulation 
(69.6%) compared to non-hypercoagulation 
(30.4%).14 Accompanying conditions are 
associated with an increased risk of cancer-
related thrombosis. Co-morbid conditions 
such as kidney failure, respiratory disease, 
heart disease, obesity and acute infections are 
associated with an increased risk of VTE in 
cancer patients.17 
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Smoking as a accompanying condition 
was found in 4.8% of patients with CNS 
tumors, no significant differences in smoking 
factors were found between hypercoagulable 
and non-hypercoagulable patients. This is in 
line with the research of Zhang et al., Which 
found no significant differences in smoking 
factors between VTE and non-VTE 
patients.18 Cigarettes are known to have an 
important role in the pathogenesis of VTE, 
through elevation in fibrinogen levels. 
Although this mechanism is unclear and there 
are many factors that can cause an increase in 
fibrinogen levels, several studies have 
reported an increase in fibrinogen levels in 
active smokers.19 
Tumor factor itself can not be 
determined whether the type and number of 
tumor lesions that affect the condition of 
hypercoagulation. In the study the number of 
lesions was significant for the incidence of 
hypercoagulation. A similar finding was 
found in research conducted by Suega and 
colleagues who explained that the number of 
tumor lesions did not have a significant 
correlation between coagulation markers and 
the type of malignancy that classified primary 
(single) and secondary (multiple) tumors. 
The research of Setiawan et al. also received 
similar results. Research by Suega et al. 
shows that primary tumor classification and 
metastasis have higher preoperative D-dimer 
levels in patients with larger and multiple 
tumor volumes.7,20 
 
5. Conclusion 
 
In this study showed that the incidence of 
hypercoagulation in patients with CNS 
tumors is very high, where there is no 
significant difference in groups who have 
accompanying conditions and without 
accompanying conditions. There are no 
factors that significantly influence the 
incidence of hypercoagulation in patients 
with CNS tumors. This research itself is an 
observational study based on the results of 
medical records where there is a possibility of 
data bias that affects the results of the 
analysis. 
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